Flexion Therapeutics

Flexion Therapeutics advances drug candidates through clinical proof of concept and beyond, in partnership with pharmaceutical and biotechnology companies. By providing expertise and sharing risk, Flexion effectively expands the portfolios of its partners.

BURLINGTON, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary ZILRETTA (triamcinolone acetonide extended-release injectable suspension) net sales of approximately $24.6 million for the quarter ended March 31, 2021.

Flexion Therapeutics Announces Preliminary First-Quarter 2021 Revenue and Provides Financial Guidance for 2021

BURLINGTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Needham 20th Annual Healthcare Conference. The virtual fireside chat is scheduled to begin at 9:30 a.m. ET on Thursday, April 15, 2021.

Flexion Therapeutics to Present at the Needham 20th Annual Virtual Healthcare Conference

Abercrombie & Fitch

Pfizer

Teva Pharmaceutical

Danaher

Jazz Pharmaceuticals

With the trading day approaching halfway over, the broad markets were trading marginally positive.

Abercrombie, Pfizer, Teva and More of Wednesday Afternoon Analyst Calls

BURLINGTON, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the treatment of the first patient in a Phase 1b proof-of-concept trial evaluating the safety and tolerability of FX301 administered as a single-dose, popliteal fossa block (a commonly used nerve block in foot and ankle-related surgeries) in patients undergoing bunionectomy.

Flexion Therapeutics Announces First Patient Treated in FX301 Phase 1b Trial for Management of Post-Operative Pain

BURLINGTON, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Oppenheimer 31st Annual Healthcare Conference. The virtual fireside chat is scheduled to begin at 10:00 a.m. ET on Wednesday, March 17, 2021.

Flexion Therapeutics to Present at the Oppenheimer 31st Annual Virtual Healthcare Conference

Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of 9.09% and -1.09%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Flexion Therapeutics (FLXN) Reports Q4 Loss, Misses Revenue Estimates

Flexion Therapeutics, Inc. (FLXN) CEO Michael Clayman on Q4 2020 Results - Earnings Call Transcript

Shares of Flexion Therapeutics (NASDAQ:FLXN) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 57.47% over the past year to ($0.37), which beat the estimate of ($0.46).

Flexion Therapeutics: Q4 Earnings Insights

BURLINGTON, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter and the full year ended December 31, 2020.

Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2020 Financial Results

Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Flexion Therapeutics (FLXN) Report Negative Q4 Earnings? What You Should Know

BURLINGTON, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2020 financial results after the close of the U.S. financial markets on Wednesday, March 10, 2021.

Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2020 Financial Results on March 10, 2021

The FDA signed off Flexion Therapeutics Inc's (NASDAQ: FLXN) Phase 1b proof of concept trial evaluating FX301 administered as a popliteal fossa block (a commonly used nerve block in the foot and ankle-related surgeries) in patients undergoing bunionectomy. FX301 combines NaV1.7 inhibitor (funapide) with thermosensitive hydrogel to facilitate administration as a peripheral analgesic nerve block.

Flexion Therapeutics To Start Testing FX301 For Post-Op Pain In Patients After Musculoskeletal Surgery

BURLINGTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the U.S. Food and Drug Administration (FDA) cleared the Investigational New Drug (IND) application for FX301, a locally administered NaV1.7 inhibitor known as funapide, formulated for extended-release in a thermosensitive hydrogel. The selective pharmacology of funapide holds the potential to provide effective non-opioid pain relief for at least 3 to 5 days, while preserving extremity motor function which is typically compromised by local anesthetic peripheral nerve block.

Flexion Therapeutics Announces FDA Clearance of Investigational New Drug Application for FX301, a Novel Formulation of a Locally Administered NaV1.7 Inhibitor for Post-Operative Pain

BURLINGTON, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 42nd Annual Raymond James Institutional Investors Conference. The virtual fireside chat is scheduled to begin at 12:30 p.m. ET on Monday, March 1, 2021.

Flexion Therapeutics to Present at the 42nd Annual Raymond James Virtual Institutional Investors Conference

Flexion Therapeutics Inc (NASDAQ: FLXN) plans to advance FX201 into the high dose cohort of Phase 1 dose-escalation trial, evaluating the safety and tolerability of FX201 for the treatment of osteoarthritis (OA). The decision follows an independent Data Monitoring Committee (DMC) review of the mid-dose safety data.

Flexion To Test Higher Dose Of FX201 Gene Therapy In Early-Stage Osteoarthritis Study

- Sheryl Swoopes, WNBA Legend, Basketball Hall of Famer and ZILRETTA Patient, Tips Off Educational Campaign About ZILRETTA and Osteoarthritis Knee Pain - Sheryl Swoopes, WNBA Legend, Basketball Hall of Famer and ZILRETTA Patient, Tips Off Educational Campaign About ZILRETTA and Osteoarthritis Knee Pain

National Basketball Retired Players Association, Sheryl Swoopes and Flexion Therapeutics Announce Partnership to Raise Awareness of ZILRETTA®

Flexion Therapeutics recently reported their Q4 and full-year 2020 results that revealed record sales for ZILRETTA and encouraging commercial metrics. Despite the COVID-19 headwinds, the company continues to report growth and commercial prowess. I believe ZILRETTA's extended release properties makes it a go-to during the pandemic.

Flexion Therapeutics: Fighting Through COVID-19 Headwinds

BURLINGTON, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced preliminary and unaudited net sales for the fourth quarter and full year ended December 31, 2020.

Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2020 Results

BURLINGTON, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the ICR | Westwicke Investment Conference. The virtual fireside chat is scheduled to begin at 10:45 a.m. ET on Thursday, January 14, 2021.

Flexion Therapeutics to Present at the ICR | Westwicke Investment Conference

BURLINGTON, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics Conference. The virtual fireside chat is scheduled to begin at 2:15 p.m. ET on Friday, December 11, 2020.

Flexion Therapeutics to Present at the Needham Virtual Epilepsy and Pain Specialty CNS Therapeutics Conference

BURLINGTON, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference. The virtual fireside chat is scheduled to begin at 8:45 a.m. ET on Wednesday, November 11, 2020.

Flexion Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference

Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -2.04% and 0.31%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Flexion Therapeutics (FLXN) Reports Q3 Loss, Tops Revenue Estimates

BURLINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended September 30, 2020.

Flexion Therapeutics Reports Third-Quarter 2020 Financial Results and Recent Business Highlights

Miller Value Partners recently released its Q3 2020 Investor Letter, a copy of which you can download here. The Opportunity Equity Fund posted a return of 13.01% for the quarter (net of fees), outperforming its benchmark, the S&P 500 Index which returned 8.93% in the same quarter. You should check out Miller Value Partners' top 5 stock picks for investors to buy right now, which could be the biggest winners of this year.

Why Flexion Therapeutics (FLXN) Stock is a Compelling Investment Case

BURLINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2020 financial results after the close of the U.S. financial markets on Wednesday, November 4, 2020.

News for Flexion Therapeutics Stock (FLXN)